TKT and glioblastoma: A significant decrease in tumor growth and a subsequent increase in survival were observed when mice bearing highly aggressive GBM were treated with MSC co-expressing S-TRAIL and HSV-TK [131], while sequential combination gene therapy using MSC/dTRAIL-TK achieved long-term remission of metastatic renal cell carcinoma without noticeable toxicity [132].